Imagen del editor

Special Report On Gene Therapy

K. K. JAIN

0 valoraciones por GoodReads
ISBN 10: 0471492906 / ISBN 13: 9780471492900
Editorial: John Wiley & Sons, 2000
Nuevos Condición: New
Librería: LIMEROCK BOOKS INC. (SARASOTA, FL, Estados Unidos de America)

Librería en AbeBooks desde: 16 de abril de 2012

Valoración librería Valoración 5 estrellas

Cantidad: 2

Disponible en otras librerías

Ver todos  los ejemplares de este libro
Comprar nuevo
Precio: EUR 269,95 Convertir moneda
Gastos de envío: EUR 23,11 De Estados Unidos de America a España Destinos, gastos y plazos de envío
Añadir al carrito

Métodos de pago
aceptados por la librería

Visa Mastercard American Express Carte Bleue

Descripción

This Book is in Good Condition; Fast Shipping !!! Delivery Time 4-7 days. 100% Money back Guaranteed!!!. N° de ref. de la librería 0471492906

Hacer una pregunta a la librería

Detalles bibliográficos

Título: Special Report On Gene Therapy

Editorial: John Wiley & Sons

Año de publicación: 2000

Condición del libro:New

Tipo de libro: book

Acerca de

Sinopsis:

This special report provides an up-to-date overview on the gene therapy industry and contains a wealth of practical information on 105 companies. For each company, information is available on the people to contact, their contact details, a corporate history, the company's technologies and products, financial data, patents held, products in clinical trials, collaborations with other companies and selected publications from the company's scientists.

Almost 200 companies were initially considered for inclusion but just over 100 companies were finally selected as they fulfilled the necessary critieria to be classified as a 'Gene Therapy Company' defined broadly to include cell therapy companies. As part of this project, new companies were discovered that have not been reported in other publications or on the internet.

Dr Jain has spared no effort to ensure that the information is up-to-date and accurate at the time of publishing. In most instances, the information was reviewed by the companies to correct any outdated information or to add any complementary or recent information.

In addition to the detailed descriptions of each company, the data is also presented in summary tabular form so that at a glance the reader can identify collaborations within the gene therapy industry, or determine which companies are pursuing strategies involving viral, non-viral, or other approaches to gene therapy, and which diseases are being targetted. Given that much of the gene therapy research and development is currently being carried out within the industrial sector, it is important for scientists, managers, and investors to have the relevant information at their fingertips. This special report provides that information in one accurate, easy to consult and up-to-date source.

Contraportada:

This special report on Gene Therapy Companies by K.K. Jain provides an up-to-date overview of the gene therapy industry. It contains a wealth of very practical information on 105 companies. For each company, information is available on the people to contact, their contact details, a corporate history, the company's technologies and products, financial data, patents held, products in clinical trials, collaborations with other companies and selected publications from the company's scientists. Almost 200 companies were initially considered for inclusion but just over 100 companies were finally selected as they fulfilled the necessary criteria to be classified as a 'Gene Therapy Company,', defined broadly to include cell therapy companies. Not all of the companies devote their activity exclusively to gene therapy but they have sufficient relevance to be included. As part of this project, new companies were discovered that have not been reported in other publications or on the internet. Dr. Jain has spared no effort to ensure that the information is up-to-date and accurate at the time of publishing. In most instances, the information was reviewed by the companies to correct any outdated information or to add any complementary or recent information. In addition to the detailed descriptions of each company, the data is also presented in summary tabular form so that at a glance the reader can identify collaborations within the gene therapy industry, or determine which companies are pursuing strategies involving viral, non-viral or other approaches to gene therapy, and which diseases are being targetted. Given that much of the gene therapy research and development is currently being carried out within the industrial sector, it is important for scientists, managers and investors to have the relevant information at their fingertips. This special report provides that information in one accurate, easy to consult and up-to-date source.

"Sobre este título" puede pertenecer a otra edición de este libro.